Surmodics Inc (SRDX)

$34.55

+1.22

(+3.66%)▲

Market is closed - opens 7 PM, 03 May 2024

Insights on Surmodics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 27.97M → 30.55M (in $), with an average increase of 8.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 7.34M → -786.0K (in $), with an average decrease of 60.3% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 104.5%

Performance

  • $33.25
    $35.48
    $34.55
    downward going graph

    3.76%

    Downside

    Day's Volatility :6.28%

    Upside

    2.62%

    downward going graph
  • $16.79
    $39.41
    $34.55
    downward going graph

    51.4%

    Downside

    52 Weeks Volatility :57.4%

    Upside

    12.33%

    downward going graph

Returns

PeriodSurmodics IncSector (Health Care)Index (Russel 2000)
3 Months
12.36%
-1.1%
0.0%
6 Months
11.27%
10.3%
0.0%
1 Year
50.09%
5.3%
1.7%
3 Years
-39.4%
14.5%
-22.3%

Highlights

Market Capitalization
371.1M
Book Value
$8.58
Earnings Per Share (EPS)
0.39
PE Ratio
66.85
PEG Ratio
3.9
Wall Street Target Price
59.0
Profit Margin
4.0%
Operating Margin TTM
-1.05%
Return On Assets TTM
4.47%
Return On Equity TTM
4.81%
Revenue TTM
138.2M
Revenue Per Share TTM
9.83
Quarterly Revenue Growth YOY
22.5%
Gross Profit TTM
29.0M
EBITDA
21.2M
Diluted Eps TTM
0.39
Quarterly Earnings Growth YOY
4.36
EPS Estimate Current Year
-0.94
EPS Estimate Next Year
-0.29
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.39

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Surmodics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 70.77%

Current $34.55
Target $59.00

Company Financials

FY18Y/Y Change
Revenue
81.3M
↑ 11.25%
Net Income
-4.5M
↓ 213.53%
Net Profit Margin
-5.48%
↓ 10.85%
FY19Y/Y Change
Revenue
100.1M
↑ 23.04%
Net Income
7.6M
↓ 270.34%
Net Profit Margin
7.59%
↑ 13.07%
FY20Y/Y Change
Revenue
94.9M
↓ 5.21%
Net Income
1.1M
↓ 85.21%
Net Profit Margin
1.18%
↓ 6.41%
FY21Y/Y Change
Revenue
105.1M
↑ 10.83%
Net Income
4.2M
↑ 277.29%
Net Profit Margin
4.03%
↑ 2.85%
FY22Y/Y Change
Revenue
100.0M
↓ 4.93%
Net Income
-27.3M
↓ 743.71%
Net Profit Margin
-27.29%
↓ 31.32%
FY23Y/Y Change
Revenue
132.6M
↑ 32.65%
Net Income
-1.5M
↓ 94.37%
Net Profit Margin
-1.16%
↑ 26.13%
Q3 FY22Q/Q Change
Revenue
26.0M
↑ 4.56%
Net Income
-14.7M
↑ 160.63%
Net Profit Margin
-56.67%
↓ 33.93%
Q4 FY22Q/Q Change
Revenue
24.9M
↓ 4.06%
Net Income
-7.8M
↓ 46.75%
Net Profit Margin
-31.46%
↑ 25.21%
Q1 FY23Q/Q Change
Revenue
27.2M
↑ 9.08%
Net Income
-7.7M
↓ 1.4%
Net Profit Margin
-28.43%
↑ 3.03%
Q2 FY23Q/Q Change
Revenue
52.5M
↑ 92.97%
Net Income
7.3M
↓ 195.0%
Net Profit Margin
14.0%
↑ 42.43%
Q3 FY23Q/Q Change
Revenue
28.0M
↓ 46.71%
Net Income
6.7M
↓ 8.88%
Net Profit Margin
23.93%
↑ 9.93%
Q4 FY23Q/Q Change
Revenue
30.6M
↑ 9.23%
Net Income
-786.0K
↓ 111.74%
Net Profit Margin
-2.57%
↓ 26.5%
FY18Y/Y Change
Total Assets
164.1M
↑ 20.16%
Total Liabilities
55.5M
↑ 121.78%
FY19Y/Y Change
Total Assets
159.9M
↓ 2.6%
Total Liabilities
37.3M
↓ 32.73%
FY20Y/Y Change
Total Assets
168.8M
↑ 5.57%
Total Liabilities
37.7M
↑ 0.96%
FY21Y/Y Change
Total Assets
194.6M
↑ 15.3%
Total Liabilities
54.5M
↑ 44.55%
FY22Y/Y Change
Total Assets
158.4M
↓ 18.62%
Total Liabilities
50.0M
↓ 8.33%
FY23Y/Y Change
Total Assets
185.7M
↑ 17.29%
Total Liabilities
65.8M
↑ 31.73%
Q3 FY22Q/Q Change
Total Assets
158.4M
↓ 9.85%
Total Liabilities
50.0M
↓ 1.13%
Q4 FY22Q/Q Change
Total Assets
169.8M
↑ 7.2%
Total Liabilities
62.5M
↑ 25.07%
Q1 FY23Q/Q Change
Total Assets
166.2M
↓ 2.12%
Total Liabilities
63.6M
↑ 1.78%
Q2 FY23Q/Q Change
Total Assets
188.9M
↑ 13.68%
Total Liabilities
76.5M
↑ 20.25%
Q3 FY23Q/Q Change
Total Assets
185.7M
↓ 1.68%
Total Liabilities
65.8M
↓ 13.94%
Q4 FY23Q/Q Change
Total Assets
180.2M
↓ 2.96%
Total Liabilities
58.1M
↓ 11.75%
FY18Y/Y Change
Operating Cash Flow
34.1M
↑ 142.31%
Investing Cash Flow
-23.5M
↑ 45.16%
Financing Cash Flow
-3.4M
↓ 47.88%
FY19Y/Y Change
Operating Cash Flow
8.0M
↓ 76.39%
Investing Cash Flow
9.8M
↓ 141.51%
Financing Cash Flow
-11.0M
↑ 225.05%
FY20Y/Y Change
Operating Cash Flow
14.0M
↑ 74.3%
Investing Cash Flow
-9.1M
↓ 192.95%
Financing Cash Flow
-4.6M
↓ 57.86%
FY21Y/Y Change
Operating Cash Flow
15.4M
↑ 9.84%
Investing Cash Flow
-25.2M
↑ 178.38%
Financing Cash Flow
10.2M
↓ 320.03%
FY22Y/Y Change
Operating Cash Flow
-17.2M
↓ 211.92%
Investing Cash Flow
6.2M
↓ 124.68%
Financing Cash Flow
-375.0K
↓ 103.67%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.5M
↓ 28.51%
Investing Cash Flow
1.4M
↓ 265.85%
Financing Cash Flow
298.0K
↓ 2392.31%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.8M
↑ 332.08%
Investing Cash Flow
-977.0K
↓ 168.42%
Financing Cash Flow
18.8M
↑ 6208.72%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.8M
↓ 46.07%
Investing Cash Flow
-723.0K
↓ 26.0%
Financing Cash Flow
-794.0K
↓ 104.22%
Q2 FY23Q/Q Change
Operating Cash Flow
25.9M
↓ 544.48%
Investing Cash Flow
-470.0K
↓ 34.99%
Financing Cash Flow
-19.0K
↓ 97.61%

Technicals Summary

Sell

Neutral

Buy

Surmodics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Surmodics Inc
Surmodics Inc
28.15%
11.27%
50.09%
-39.4%
-23.78%
Stryker Corporation
Stryker Corporation
-6.94%
18.25%
13.75%
24.15%
71.27%
Boston Scientific Corp.
Boston Scientific Corp.
5.72%
37.12%
36.71%
65.09%
93.63%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-8.56%
26.82%
-3.45%
-10.11%
40.59%
Abbott Laboratories
Abbott Laboratories
-4.82%
10.52%
-5.23%
-11.39%
34.6%
Medtronic Plc
Medtronic Plc
-4.8%
11.52%
-10.77%
-38.32%
-9.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Surmodics Inc
Surmodics Inc
66.85
66.85
3.9
-0.94
0.05
0.04
NA
8.58
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.58
37.58
5.19
2.75
0.21
0.12
NA
11.83
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Surmodics Inc
Surmodics Inc
Buy
$371.1M
-23.78%
66.85
4.0%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
71.27%
40.83
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
93.63%
68.14
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.0B
40.59%
37.58
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
34.6%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-9.67%
25.52
13.0%

Institutional Holdings

  • Trigran Investments Inc

    16.57%

  • Morgan Stanley - Brokerage Accounts

    8.72%

  • BlackRock Inc

    7.59%

  • Vanguard Group Inc

    6.04%

  • Soleus Capital Management, L.P.

    5.42%

  • Millennium Management LLC

    4.72%

Company Information

surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.

Organization
Surmodics Inc
Employees
376
CEO
Mr. Gary R. Maharaj
Industry
Health Technology

Discover More

FAQs